Product Categories

Dalcetrapib (JTT-705)

Dalcetrapib (JTT-705) is a rhCETP inhibitor with IC50 of 0.2 μM.

Catalog No.S2772
Price Stock Quantity  
USD 270 In stock
USD 470 In stock
USD 1670 In stock
USD 2470 In stock
Contact Us Bulk Inquiry Add to Wishlist

Free Overnight Delivery on all orders over $ 500.

Order now and get it on

Tel: +1-832-582-8158[email protected]

Dalcetrapib (JTT-705) Chemical Structure
Molecular Weight: 389.59

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

Dalcetrapib (JTT-705) is available in the following compound libraries:

Cambridge Cancer Compound Library(96-well) Chemical Library (96-well) Inhibitor Library (96-well)

Product Information

  • Compare CETP Inhibitors
    Compare CETP Inhibitors
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity Protocol Chemical Information Tech Support & FAQs

Biological Activity

Description Dalcetrapib (JTT-705) is a rhCETP inhibitor with IC50 of 0.2 μM.
Targets rhCETP
IC50 0.2 μM [1]
In vitro Dalcetrapib modulates CETP activity. Dalcetrapib induces a conformational change in CETP, when added to human plasma. CETP-induced pre-β-HDL formation in human plasma is unchanged by Dalcetrapib ≤3 µM and increased at 10 µM. Dalcetrapib statistically and significantly increases pre-β-HDL formation. [1] Dalcetrapib achieves 50% inhibition of CETP activity in human plasma at a concentration of 9 μM. [2] Dalcetrapib inhibits the CETP activity of media in HepG2 in a dose-dependent manner. [3]
In vivo Treatment with Dalcetrapib leads to significant increases in HDL-C levels. In hamsters injected with [3H]cholesterol-labeled autologous macrophages Dalcetrapib significantly increases fecal elimination of both [3H]neutral sterols and [3H]bile acids. Dalcetrapib increases plasma HDL-[3H]cholesterol. [1] Dalcetrapib has 95% inhibition of CETP activity in male Japanese white rabbits at an oral dose of 30 mg/kg. Dalcetrapib increases the plasma HDL cholesterol level by 27% and 54%, respectively, when given at oral doses of 30 mg/kg or 100 mg/kg once a day for 3 days to male Japanese white rabbits. [2] Treatment with Dalcetrapib markedly increases serum levels of HDL-C. The ratio of HDL2-C to HDL3-C is significantly higher in Dalcetrapib–treated rabbits than in control rabbits at 5 and 7 months, indicating that the inhibition of CETP activity by Dalcetrapib changes the distribution of HDL subfractions and preferentially increases HDL2-C levels. Dalcetrapib treatment increases serum paraoxonase activity and HDL-associated platelet-activating factor acetylhydrolase activity, but decreases the plasma lysophosphatidylcholine concentration. [4]
Clinical Trials Dalcetrapib has enered in a Phase III clinical trial in the treatment of cardiovascular disease, dyslipidemia, peripheral arterial disease (PAD).
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Inhibition of rhCETP and C13S CETP-mediated transfer of CE from HDL to LDL The inhibitory potency (IC50) of Dalcetrapib to decrease CE transfer from HDL to LDL by rhCETP and C13S CETP is measured using a scintillation proximity assay kit. Briefly, [3H]CE-labeled HDL donor particles are incubated in the presence of purified CETP proteins (final concentration 0.5 µg/mL) and biotinylated LDL acceptor particles for 3 hours at 37 °C. Subsequently, streptavidin-coupled polyvinyltoluene beads containing liquid scintillation cocktail binding selectively to biotinylated LDL are added, and the amount of [3H]CE molecules transferred to LDL is measured by β counting.

Cell Assay: [3]

Cell lines HepG2 cells
Concentrations 0-30 μM
Incubation Time 24 hours
Method The HepG2 cells are seeded in 6-well plates and cultured to 70–80% confluence. After being washed with PBS, the cells are incubated with growth medium and a different concentration (0 μM–30 μM) of chemical inhibitor Dalcetrapib and dissolved in 2% DMSO for 24 hours. Total RNA is used for RT-PCR.

Animal Study: [1]

Animal Models Syrian hamsters
Formulation 0.5% methylcellulose
Dosages 100 mg/kg
Administration Oral gavage
1

References

Chemical Information

Download Dalcetrapib (JTT-705) SDF
Molecular Weight (MW) 389.59
Formula

C23H35NO2S
CAS No. 211513-37-0
Synonyms N/A
Solubility (25°C)
  • DMSO 78 mg/mL
  • Water <1 mg/mL
  • Ethanol 78 mg/mL
Storage 2 years -20°CPowder
2 weeks4°Cin DMSO
6 months-80°Cin DMSO
Chemical Name S-2-(1-(2-ethylbutyl)cyclohexanecarboxamido)phenyl 2-methylpropanethioate
Molarity Calculator Dilution Calculator Molecular Weight Calculator

Research Area

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions
Tel: +1-832-582-8158 Ext:3Monday–Friday 9:00 AM–5:00 PM (Central Time)

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related CETP Inhibitors

  • Anacetrapib (MK-0859)

    Anacetrapib (MK0859) is a potent and selective rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, respectively

  • Torcetrapib (CP-529414)

    Torcetrapib (CP-529414) is a CETP inhibitor with IC50 of 37 nM.

  • Evacetrapib (LY2484595)

    LY2484595 is a potent and selective inhibitor of CETP with IC50 of 5.5 nM.

  • Varespladib (LY315920)

    LY315920 (Varespladib) is a potent and selective secretory phospholipase A2 (sPLA) inhibitor with IC50 of 7 nM.

  • MK-8245

    MK-8245 is an inhibitor of stearoyl-CoA desaturase (SCD) which targets the liver with IC50 of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1.

  • TAK-700 (Orteronel)

    TAK-700 (Orteronel) is a potent and highly selective rat and human 17,20-lyase inhibitor with IC50 of 54 nM and 38 nM, respectively.

  • Tipifarnib (Zarnestra)

    Tipifarnib (Zarnestra, R115777) is a potent and specific farnesyltransferase (FTase) inhibitor with IC50 of 0.6 nM.

  • Cilomilast (SB-207499)

    Cilomilast (SB-207499) is a potent LPDE4 and HPDE4 inhibitor with IC50 of 100 nM and 120 nM, respectively.

  • Safinamide Mesylate (FCE28073)

    Safinamide Mesylate is mesylate salt of Safinamide, which selectively and reversibly inhibits MAO-B with IC50 of 0.45 μM.

  • GW501516

    GW501516 is a selective PPARδ agonist with Ki of 1.1 nM.

Recently Viewed Items

Tags: buy Dalcetrapib (JTT-705) | Dalcetrapib (JTT-705) supplier | purchase Dalcetrapib (JTT-705) | Dalcetrapib (JTT-705) cost | Dalcetrapib (JTT-705) manufacturer | order Dalcetrapib (JTT-705) | Dalcetrapib (JTT-705) distributor
Contact Us